Development of Tinzaparin: A Heparinase-Digested Low-Molecular-Weight Heparin

ABSTRACT

Although heparin and its properties had been discovered in the early 1920s, the different characteristics associated with different molecular-weight fractions of heparin were only recognized in the late 1970s. Tinzaparin is a low-molecular-weight heparin (LMWH) produced by heparinase digestion of heparin. Preclinical research on tinzaparin established that there were no differences in the antithrombotic activity compared with heparin. Clinical studies evaluating tinzaparin vs. standard heparin for thromboprophylaxis of deep-vein thrombosis in general and orthopedic surgery found that tinzaparin was as effective as standard heparin. Tinzaparin was also evaluated vs. standard heparin in the treatment of acute proximal vein thrombosis; time-to-event curves suggested that this LMWH could be more effective than standard heparin.

KEYWORD

Tinzaparin - development - thromboprophylaxis - treatment of deep-vein thrombosis

REFERENCES

• 1 Crafoord C. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis.  Acta Chir Scand Suppl . 1936;  79 407-413
• 2 Crafoord C, Jorpes J. Heparin as a prophylaxis against thrombosis.  JAMA . 1941;  111 2831-2840
• 3 Laurent T C. Studies on fractionated heparin.  Arch Biochem Biophys . 1961;  92 224-231
• 4 Johnson E A, Mulloy B. The molecular-weight range of mucosal-heparin preparations.  Carbohydr Res . 1976;  51 119-127
• 5 Denson K W, Bonnar J. The measurement of heparin. A method based on the potentiation of anti-factor Xa.  Thromb Diath Haemorrh . 1973;  30 471-479
• 6 Yin E T, Wessler S, Butler J V. Plasma heparin: A unique, practical, submicrogram-sensitive assay.  J Lab Clin Med . 1973;  81 298-310
• 7 Brinkhous K M, Smith H W, Warner E D, Seegers W H. The inhibition of blood clotting: An unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin to thrombin.  Am J Physiol . 1939;  125 683-687
• 8 Abildgaard U. Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis.  Scand J Clin Lab Invest . 1968;  21 89-91
• 9 Yin E T, Wessler S, Stoll P J. Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor.  J Biol Chem . 1971;  246 3712-3719
• 10 Yin E T, Wessler S, Stoll P J. Biological properties of the naturally occurring plasma inhibitor to activated factor X.  J Biol Chem . 1971;  246 3703-3711
• 11 Rosenberg R D, Damus P S. The purification and mechanism of action of human antithrombin-heparin cofactor.  J Biol Chem . 1973;  248 6490-6505
• 12 Rosenberg R D. Actions and interactions of antithrombin and heparin.  N Engl J Med . 1975;  292 146-151
• 13 Friedel H A, Balfour J A. Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.  Drugs . 1994;  48 638-660
• 14 Nielsen J I, Østergaard P. Chemistry of heparin and low molecular weight heparin.  Acta Chir Scand Suppl . 1988;  543 52-56
• 15 Fareed J, Walenga J M, Hoppensteadt D, Huan X, Nonn R. Biochemical and pharmacologic inequivalence of low molecular weight heparins.  Ann N Y Acad Sci . 1989;  556 333-353
• 16 Bendetowicz A-V, Pacaud E, Beguin S, Uzan A, Hemker H C. On the relationship between molecular mass and anticoagulant activity in a low molecular weight heparin enoxaparin.  Thromb Haemost . 1992;  67 556-562
• 17 Mätzsch T, Bergqvist D, Bergqvist A. No transplacental passage of standard heparin or an enzymatically depolymerized low molecular weight heparin.  Blood Coagul Fibrinolysis . 1991;  2 273-278
• 18 Pedersen P C, Østergaard P B, Hedner U, Bergqvist D, Mätzsch T. Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers.  Thromb Res . 1991;  61 477-487
• 19 Mätzsch T, Bergqvist D, Hedner U, Østergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers.  Thromb Haemost . 1987;  57 97-101
• 20 Fareed J, Walenga J M, Hoppensteadt D, Racanelli A, Coyne E. Chemical and biological heterogeneity in low molecular weight heparins: Implications for clinical use and standardization.  Semin Thromb Hemost . 1989;  15 440-463
• 21 Johnson E A. Comment on two papers by Dr. J. Fareed.  Haemostasis . 1989;  19 51-64
• 22 Østergaard P B, Nilsson B, Bergqvist D, Hedner U, Pedersen P C. The effect of low molecular weight heparin on experimental thrombosis and haemostasis-The influence of production method.  Thromb Res . 1987;  45 739-749
• 23 Diness V, Nielsen J I, Pedersen P C, Wolffbrandt K H, Østergaard P B. A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin.  Thromb Haemost . 1986;  55 410-414
• 24 Diness V, Østergaard P B. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.  Thromb Haemost . 1986;  56 318-322
• 25 Mätzsch T, Bergqvist D, Hedner U, Nilsson B, Østergaard P. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats.  Thromb Haemost . 1990;  63 505-509
• 26 Flessa H C, Kapstrom A B, Glueck H I, Will J J. Placental transport of heparin.  Am J Obstet Gynecol . 1965;  93 570-573
• 27 Omri A, Delaloye J F, Andersen H, Bachmann F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy.  Thromb Haemost . 1989;  61 55-56
• 28 Dawes J, Prowse C V, Pepper D S. The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine.  Thromb Haemost . 1985;  54 630-634
• 29 Liezorovicz A, Picolet H, Peyrieux J C, Boissel J P. Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group.  Br J Surg . 1991;  78 412-416
• 30 Hull R, Raskob G, Pineo G. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.  N Engl J Med . 1993;  329 1370-1376
• 31 Mätzsch T, Bergqvist D, Fredin H. Comparison of the thromboprophylactic effect of a low molecular weight heparin versus dextran in total hip replacement.  Thromb Haemorrh Dis . 1991;  3 25-29
• 32 Siegbahn A, Y-Hassan S, Boberg J. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo.  Thromb Res . 1989;  55 767-778
• 33 Hull R D, Raskob G E, Pineo G F. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.  N Engl J Med . 1992;  326 975-982
• 34 Mätzsch T, Bergqvist D, Fredin H. Comparison of the thromboprophylactic effect of a low molecular weight heparin versus dextran in total hip replacement.  Thromb Haemorr Dis . 1991;  3 25-29
• 35 Green D, Lee M Y, Lim A C. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin.  Ann Intern Med . 1990;  113 571-574